Literature DB >> 1505120

Isolation and characterization of a low metastatic variant from EL-4 mouse T-lymphoma.

T Ota1, M Tanino, H Kohno, H Funamoto, S Odashima.   

Abstract

A variant cell line (EL-4ad) which adhered to a tissue culture dish was isolated from highly metastatic EL-4 murine T-lymphoma. The experimental and spontaneous metastatic ability of EL-4ad was lower than that of the EL-4 parent cell line. The cell surface phenotypes of both cell lines were CD2+3+4-8-45+TCR alpha beta+TCR gamma delta-, but the level of CD2 expression of EL-4ad was much lower than that of EL-4. Furthermore, EL-4ad had higher binding ability to fibronectin and expressed more PNA receptors on the cell surface than EL-4. These differences indicated that either the maturation stage of the less metastatic variant was lower than that of the parent cell line or the activation state of the two cell lines differed. EL-4ad showed higher in vitro invasiveness and adhesiveness to liver cells, and these characters were not consistent with the reduced metastatic ability of this variant. Neuraminidase-releasable cell surface sialic acid levels did not differ significantly between the cell lines. Neither cell line was adhesive to laminin, type IV collagen or reconstituted basement membrane. These metastasis-related properties could not explain the decreased metastatic ability of EL-4ad. On the other hand, EL-4ad was more sensitive to NK activity than EL-4 in vivo, and this was thought to be a major cause of its decreased metastatic ability. The molecules or mechanisms involved in the differentiation or activation of T-cells may be responsible for the sensitivity of tumor cells to NK activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1505120     DOI: 10.1007/bf00058169

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  51 in total

1.  Induction of phenotypic reverse transformation by ginsenosides in cultured Morris hepatoma cells.

Authors:  S Odashima; Y Nakayabu; N Honjo; H Abe; S Arichi
Journal:  Eur J Cancer       Date:  1979-06       Impact factor: 9.162

2.  Lysis of a lung carcinoma by poly I:C-induced natural killer cells is independent of the expression of class I histocompatibility antigens.

Authors:  G Dennert; C Landon; E M Lord; D W Bahler; J G Frelinger
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

3.  A new in vitro assay for quantitating tumor cell invasion.

Authors:  L A Repesh
Journal:  Invasion Metastasis       Date:  1989

4.  Molecular analysis of H-2-deficient lymphoma lines. Distinct defects in biosynthesis and association of MHC class I heavy chains and beta 2-microglobulin observed in cells with increased sensitivity to NK cell lysis.

Authors:  H G Ljunggren; S Pääbo; M Cochet; G Kling; P Kourilsky; K Kärre
Journal:  J Immunol       Date:  1989-04-15       Impact factor: 5.422

Review 5.  The differentiation of myeloid leukaemia cells: new possibilities for therapy.

Authors:  L Sachs
Journal:  Br J Haematol       Date:  1978-12       Impact factor: 6.998

6.  Peanut agglutinin. I. A new tool for studying T lymphocyte subpopulations.

Authors:  J London; S Berrih; J F Bach
Journal:  J Immunol       Date:  1978-08       Impact factor: 5.422

7.  Separation of mouse T cell subsets by a fluorescent activated cell sorter using fluorescence-labeled peanut agglutinin.

Authors:  Y Imai; T Oguchi; T Nakano; T Osawa
Journal:  Immunol Commun       Date:  1979

8.  Role of natural killer cells in the destruction of circulating tumor emboli.

Authors:  N Hanna; I J Fidler
Journal:  J Natl Cancer Inst       Date:  1980-10       Impact factor: 13.506

9.  EL-4 metastases in spleen and bone marrow suppress the NK activity generated in these organs.

Authors:  M Sarzotti; S Baron; G R Klimpel
Journal:  Int J Cancer       Date:  1987-01-15       Impact factor: 7.396

10.  Preferential expression of fibronectin receptors on immature thymocytes.

Authors:  P M Cardarelli; I N Crispe; M D Pierschbacher
Journal:  J Cell Biol       Date:  1988-06       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.